Provided by Tiger Trade Technology Pte. Ltd.

Century Therapeutics, Inc.

2.13
+0.10004.93%
Post-market: 2.180.0528+2.48%19:50 EST
Volume:682.13K
Turnover:1.44M
Market Cap:383.40M
PE:-6.81
High:2.16
Open:2.06
Low:2.04
Close:2.03
52wk High:2.71
52wk Low:0.3418
Shares:180.00M
Float Shares:112.00M
Volume Ratio:0.94
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3127
EPS(LYR):-1.6093
ROE:-14.24%
ROA:-4.47%
PB:2.17
PE(LYR):-1.32

Loading ...

Century Therapeutics CEO Brent Pfeiffenberger Reports Acquisition of Common Shares

Reuters
·
Nov 21, 2025

Century Therapeutics CEO Makes Significant Stock Sale!

TIPRANKS
·
Nov 20, 2025

Century Therapeutics Shares Fall After Leerink Partners Downgrade

MT Newswires Live
·
Nov 18, 2025

Century Therapeutics (IPSC) Gets a Buy from Clear Street

TIPRANKS
·
Nov 17, 2025

Leerink Partners Downgrades Century Therapeutics to Market Perform From Outperform

MT Newswires Live
·
Nov 17, 2025

Century Therapeutics Q3 net loss widens, despite lower costs

Reuters
·
Nov 13, 2025

Century Therapeutics reports Q3 EPS (40c) vs (37c) last year

TIPRANKS
·
Nov 13, 2025

Century Therapeutics Q3 EPS $(0.40) Misses $(0.34) Estimate

Benzinga
·
Nov 13, 2025

BRIEF-Century Therapeutics Q3 Net Income USD -34.422 Million

Reuters
·
Nov 13, 2025

Century Therapeutics Q3 Operating Income USD -36.124 Million

THOMSON REUTERS
·
Nov 13, 2025

Century Therapeutics Inc - Estimates Cash Runway Into 4Q 2027

THOMSON REUTERS
·
Nov 13, 2025

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 13, 2025

Century Therapeutics Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes

Reuters
·
Nov 13, 2025

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

THOMSON REUTERS
·
Nov 13, 2025

Century Therapeutics Inc - Ind-Enabling Studies to Start by Year-End 2025, Ind Submission Planned as Early as 2026

THOMSON REUTERS
·
Nov 13, 2025

Top News Today/Canada: Barrick's Interim CEO Gets to Work

Dow Jones
·
Nov 11, 2025

Century Therapeutics’ CALiPSO-1 Study: A Promising Step in Autoimmune Disease Treatment

TIPRANKS
·
Oct 28, 2025

Century Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
Oct 24, 2025

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

GlobeNewswire
·
Oct 15, 2025

Century Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Non-Compliance with Minimum Bid Price Rule

Reuters
·
Aug 30, 2025